Drug Trial Radar · NCT04672525
Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR
Last checked: Nov 19, 2026Latest source record: May 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
436
Planned (sponsor's estimate)
Start
Nov 8, 2021
Primary completion
Nov 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Tourcoing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.
Conditions
- Prosthetic Infection
Interventions
RifabutinDrug
2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
RifampicinDrug
10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment failureTime frame: At one year
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
CHU Amiens Picardie
Amiens, France · Not yet recruiting
CHU Angers
Angers, France · Not yet recruiting
CHU Besançon
Besançon, France · Recruiting
CH de Béthune
Béthune, France · Not yet recruiting
CHU Bordeaux
Bordeaux, France · Not yet recruiting
APHP Hôpital Ambroise Paré
Boulogne-Billancourt, France · Not yet recruiting
CHRU Brest
Brest, France · Recruiting
CHU Caen
Caen, France · Recruiting
CH Alpes Leman
Contamine-sur-Arve, France · Not yet recruiting
CHU Dijon Bourgogne
Dijon, France · Not yet recruiting
CHU Grenoble Alpes
Grenoble, France · Not yet recruiting
CHRU Lille
Lille, France · Recruiting
GHICL Hôpital Saint Vincent de Paul
Lille, France · Not yet recruiting
CHU de Limoges
Limoges, France · Recruiting
GHICL Hôpital Saint Philibert
Lomme, France · Not yet recruiting
Clinique de la Sauvegarde
Lyon, France · Not yet recruiting
Hospices Civils de Lyon
Lyon, France · Not yet recruiting
APHM Hôpital Nord
Marseille, France · Not yet recruiting
CHU Nice
Nice, France · Not yet recruiting
CH Annecy Genevois
Pringy, France · Recruiting
CH Cornouaille
Quimper, France · Not yet recruiting
CHU Reims
Reims, France · Not yet recruiting
CHU de Rennes
Rennes, France · Recruiting
CHU Saint Etienne
Saint-Priest-en-Jarez, France · Not yet recruiting
CHRU Strasbourg
Strasbourg, France · Not yet recruiting
Hôpital d'instruction des armées Sainte Anne
Toulon, France · Recruiting
Clinique Joseph Ducuing
Toulouse, France · Not yet recruiting
Clinique Médipole Garonne
Toulouse, France · Not yet recruiting
CH Tourcoing
Tourcoing, France · Recruiting
CHRU Tours
Tours, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.